This trial included 33 patients with clinical node-positive locally advanced breast cancer who underwent NET and breast surgery. MRI exams were performed before the first treatment regimen, at least two months after the first treatment cycle but prior to crossing-over, and immediately before surgery. MRI did not demonstrate sufficient diagnostic performance to avoid surgical axillary staging in the authors’ analysis.

The prospective, open-label, single-arm, phase 2 TUXEDO-1 trial enrolled patients with HER2-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy. Patients received trastuzumab deruxtecan intravenously at the standard dose of 5.4 mg per kg bodyweight once every 3 weeks. Fifteen patients received at least one dose of study drug. Two patients (13.3%) had a complete intracranial response, nine (60%) had a partial intracranial response and three (20%) had stable disease as the best intracranial response. There were no new safety signals.

The Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990 included 462 postmenopausal patients with lymph node-negative breast cancer. This secondary analysis of trial data (including a 2014 tumor tissue assessment with immunohistochemistry and Agilent microarrays) looked for long-term survival benefit with tamoxifen. The authors conclude that patients with luminal A tumor subtype appeared to have a long-term (i.e., 15-year) benefit from tamoxifen therapy, and patients with luminal B subtype appeared to have an early benefit (i.e., 5 years) from therapy, when the risk of distant metastatic disease was high.

A multi-variate analysis published in Cancer Medicine, which includes a population of more than 150,000 individuals, suggests that prior cannabis use was associated with a reduced risk of renal cell carcinoma and bladder cancer in women and prostate cancer in men. A potentially conflicting finding was increased risk of some cancers in current cannabis users.

In this 3rd case in a short series, the author describes integration of next-generation PSMA imaging with conventional imaging, including CT and bone scans. The author reviews the rationale for triple therapy with darolutamide, ADT, and docetaxel, and reviews the key phase III studies on triple therapy in prostate cancer: the ENZAMET, PEACE-1 and ARASENS trials.

This large surgically staged cohort of high-risk patients with preoperative PSMA PET evaluated the accuracy of Ga-68-PSMA-PET/CT for primary nodal staging. The findings suggest that total lesion uptake values could provide valuable presurgical staging information and might aid in predicting risk of lymph node metastasis in patients with prostate cancer.